European regulators cleared Moderna’s first-of-its-kind vaccine as US approval remains uncertain. On Friday, Moderna’s ...

The recommendation from regulators paves the way for the shot’s approval in the European Union at a time the company is ...

Moderna said it met with the FDA on Tuesday to discuss the vaccine and afterward, the U.S. regulator accepted a revised ...

The World Health Organization (WHO) today announced recommendations for the viral composition of influenza (or "flu") vaccines for the 2026-2027 northern hemisphere influenza season. The announcement ...

Vaccines have traditionally worked by teaching the immune system to recognize a specific virus or bacterium—in effect, ...

The Food and Drug Administration's about-face comes a little more than a week after the agency refused to consider the ...

With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.

This prompts a reassessment of the stock’s value to determine if this represents a genuine opportunity or a potential trap.

In a sudden reversal, the U.S. Food and Drug Administration (FDA) has agreed to review Moderna’s experimental mRNA influenza vaccine.

After a year marked by an early and sharp rise in flu cases in several countries, India is set to update its seasonal ...

The company’s mRNA flu shot, if approved, could be available for the 2026-27 flu season.

The FDA will review Moderna’s new mRNA flu vaccine after reversing course, raising fresh concerns about potential setbacks ...